Navigation Links
Study shows combination stroke therapy safe and effective
Date:7/30/2013

CINCINNATI -- The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found.

Results from the study, known as the CLEAR-ER Stroke Trial, are published online in the journal Stroke: Journal of the American Heart Association. UC was the coordinating center for the trial, which included nine medical centers comprising 21 hospitals.

Standard treatment for acute ischemic stroke (characterized by an obstruction to the blood flow, typically a clot), is intravenous (IV) delivery of U.S. Food and Drug Administration-approved tissue plasminogen activator (tPA) within three hours of stroke onset.

The CLEAR-ER (Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke Enhanced Regimen) trial was a phase-2 clinical trial designed to determine the safety of an enhanced dosing regimen using eptifibatide and establish evidence for a phase-3 clinical trial, which would use a larger pool of subjects. As an antiplatelet medication, eptifibatidedelivered intravenouslyworks together with the tPA to break up the existing clot and prevents formation of additional clots by decreasing the clumping of blood platelets.

"Through our team's research efforts, we were able to determine that eptifibatide may be safely combined with medium-dose IV tPA administered within three hours of symptom onset and that a phase-3 clinical trial is warranted," says Opeolu Adeoye, MD, UC assistant professor of emergency medicine and neurosurgery and a neurointensivist at UC Medical Center.

Adeoye was co-principal investigator along with Arthur Pancioli, MD, professor and Richard C. Levy Chair for Emergency Medicine at UC. Both Adeoye and Pancioli are members of the UC Neuroscience Institute, one of four institutes affiliated with the UC College of Medicine and UC Health

Says Pancioli: "We know that the combination of these two medications dissolves clots faster and more completely than tPA alone. Our goal is to determine if we can use this combination to improve the outcomes for acute stroke victims."

CLEAR-ER investigators enrolled 126 subjects from July 2009 to October 2012. Of those, 101 received tPA plus eptifibatide and 25 received tPA alone. As the trial was a double-blind, randomized study, neither patient nor doctor was aware if the substance administered in addition to tPA was a medication or a placebo.

Investigators examined safety at specified endpoints, watching for incidence of intracerebral hemorrhage (ICH), and 90-day outcomes using a standardized measurement tool. Of the subjects who were given tPA plus eptifibatide, 50 (49.5 percent) had what were classified as good outcomes. Those who received tPA alone had nine good outcomes (36 percent).

Safety between the two groups was shown to be comparable at 36-hour, seven-day and 90-day endpoints.

The potential next step in investigation of the enhanced regimen, a phase-3 clinical trial, would typically use a larger pool of subjects determined by data from the phase-2 trial. Phase-3 trials, the last step before marketing of a medication, typically confirm its effectiveness, monitor side effects, compare it to commonly used treatments and collect information that will allow it to be used safely.


'/>"/>

Contact: Kathryn Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... financial organizations, today announced CIO Applications magazine has named the company a “Top ... innovative use of the Cloud to help organizations simply and proactively address potential cybersecurity ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... pharmaceutical and medical device sectors, today announced the winners of its 3rd Annual ... represent the most influential people in the healthcare industry today. , Out of ...
(Date:5/23/2017)... ... 23, 2017 , ... New England Journal Of Medicine Confirms Viability of Rory’s ... -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt ... http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 in ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National Council on Strength ... announce the organization’s Certified Strength Coach credential has earned accreditation from the National ... validates the competency of qualified candidates for jobs in the Strength and Conditioning ...
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery ... Kevin Sadati, is pleased to announce a new treatment option called Vivace Microneedling. ... their face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet ... in musculoskeletal healthcare, today announced it has earned a ... of 2017" list. The Company was ranked among 500 ... Large Employers and Healthcare Equipment and Services. ... based on an anonymous, independent survey of over 30,000 ...
(Date:5/8/2017)... , May 8, 2017 MACRA ... transition from fee for service reimbursement. Black Book Research ... 1.       The Market for MIPS Compliance ... 77% of physician practices with 3 or more clinicians ... Solutions by Q4. "Given the magnitude of the changes, ...
(Date:5/6/2017)... 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), has ... square feet to its Welch Allyn campus. ... to bring more than 100 new jobs to ... has maintained a significant presence for more than 100 ... positions, a large portion of which will be R&D ...
Breaking Medicine Technology: